Ardelyx traded at $0.57 this Thursday June 30th, decreasing $0.002 or 0.26 percent since the previous trading session. Looking back, over the last four weeks, Ardelyx lost 12.62 percent. Over the last 12 months, its price fell by 92.79 percent. Looking ahead, we forecast Ardelyx to be priced at 0.58 by the end of this quarter and at 0.53 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Abbott 108.19 -0.91 -0.83% -7.66%
Amgen 242.88 -2.55 -1.04% -1.63%
Ardelyx 0.57 -0.002 -0.26% -92.79%
Astrazeneca 66.38 -0.64 -0.95% 10.06%
Biocept 0.97 0.004 0.39% -77.70%
Chimerix 2.03 -0.03 -1.46% -76.80%
Corcept Therapeutics 24.09 -0.66 -2.65% 6.90%
Curis 1.00 -0.004 -0.39% -87.55%
Life Technologies 2.80 0.05 1.82% -44.00%
Opko Health 2.55 -0.05 -1.74% -39.98%
Sanofi 50.04 -2.63 -4.99% -4.79%
TG Therapeutics 4.32 0 0% -89.32%
United Therapeutics 238.08 -0.21 -0.09% 28.92%
Xoma 21.09 0.64 3.13% -37.03%

Indexes Price Day Year
USND 11039 -139.19 -1.25% -23.99%

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.